Literature DB >> 18627269

A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses.

Misako Yajima1, Ken-Ichi Imadome, Atsuko Nakagawa, Satoru Watanabe, Kazuo Terashima, Hiroyuki Nakamura, Mamoru Ito, Norio Shimizu, Mitsuo Honda, Naoki Yamamoto, Shigeyoshi Fujiwara.   

Abstract

The functional human immune system, including T, B, and natural killer lymphocytes, is reconstituted in NOD/Shi-scid/IL-2Rgamma(null) (NOG) mice that receive hematopoietic stem cell transplants. Here, we show that these humanized mice can recapitulate key aspects of Epstein-Barr virus (EBV) infection in humans. Inoculation with approximately 1 x 10(3) TD(50) (50% transforming dose) of EBV caused B cell lymphoproliferative disorder, with histopathological findings and latent EBV gene expression remarkably similar to that in immunocompromised patients. Inoculation with a low dose of virus (<or=1 x 10(1) TD(50)), in contrast, resulted in apparently asymptomatic persistent infection. Levels of activated CD8(+) T cells increased dramatically in the peripheral blood of infected mice, and enzyme-linked immunospot assay and flow cytometry demonstrated an EBV-specific T cell response. Immunoglobulin M antibody specific to the EBV-encoded protein BFRF3 was detected in serum from infected mice. The NOG mouse is the most comprehensive small-animal model of EBV infection described to date and should facilitate studies of the pathogenesis, prevention, and treatment of EBV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627269     DOI: 10.1086/590502

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  82 in total

1.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  New take on comparative immunology: relevance to immunotherapy.

Authors:  Ena Wang; Adriana Albini; David F Stroncek; Francesco M Marincola
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

3.  Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice.

Authors:  Deepika Rajesh; Ying Zhou; Ewa Jankowska-Gan; Drew Allan Roenneburg; Melanie L Dart; Jose Torrealba; William J Burlingham
Journal:  Hum Immunol       Date:  2010-03-26       Impact factor: 2.850

Review 4.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice.

Authors:  Smita Jaiswal; Pamela Pazoles; Marcia Woda; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Anuja Mathew
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

6.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 7.  Viral microRNA genomics and target validation.

Authors:  Joseph M Ziegelbauer
Journal:  Curr Opin Virol       Date:  2014-04-22       Impact factor: 7.090

8.  Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice.

Authors:  Pablo D Becker; Nicolas Legrand; Caroline M M van Geelen; Miriam Noerder; Nicholas D Huntington; Annick Lim; Etsuko Yasuda; Sean A Diehl; Ferenc A Scheeren; Michael Ott; Kees Weijer; Heiner Wedemeyer; James P Di Santo; Tim Beaumont; Carlos A Guzman; Hergen Spits
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

9.  Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.

Authors:  Obinna Chijioke; Anne Müller; Regina Feederle; Mario Henrique M Barros; Carsten Krieg; Vanessa Emmel; Emanuela Marcenaro; Carol S Leung; Olga Antsiferova; Vanessa Landtwing; Walter Bossart; Alessandro Moretta; Rocio Hassan; Onur Boyman; Gerald Niedobitek; Henri-Jacques Delecluse; Riccarda Capaul; Christian Münz
Journal:  Cell Rep       Date:  2013-12-19       Impact factor: 9.423

10.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.